AB0534 The Relationship of Pentraxin-3 Levels in Behcet Disease with IL-17, Disease Activity and Atherosclerotic Risk Factors

Background Several factors have been implicated as contributing to the risk of atherosclerosis in patients with BD. (1) These include inflammatory mediators such as cytokines and adhesion molecules and traditional cardiovascular risk factors such as age, high blood pressure, and dyslipidemia.(2) PTX3 also acts as a modulator of inflammatory processes and is involved in the development of atherosclerotic lesions. It is produced by endothelial cells in atherosclerotic plaques. Objectives With this study we aimed to identify the levels of the proteins like Pentraxin and Fetuin-A which are thought to have a role in the progress of atherosclerotic and cardiovascular disorders in Behcet disease and the relationship of these with disease activity, inflammatory cytokine, insulin resistance and dyslipidemia. Methods This study included 58 patients (36 female, 22 male) with Behcet disease and 20 healthy controls. Serum pentraxin-3, fetuin-A, IL-17 and insulin concentrations were determined. Also, HOMA-IR values were calculated. Disease activity was assessed with Behcet9s Disease Current Activity Form (BDCAF). Results PTX3 and fetuin-A levels were not correlated with ESR, CRP, and any domains of BDCAF scores. IL-17 levels were significantly positively correlated with arthritis of BDCAF scores. there wasn9t any significant relationship between the lipid profile and PTX3, IL17 and fetuin-A levels. There wasn9t any correlation between PTX and IL 17, fetuin-A, insulin, HOMA IR levels (p>0.05). Conclusions Just like CRP, PTX3 is an acute-phase reactant and it is considers as an inflammatory and atherosclerotic biomarker. In this study, we presented that PTX3 can increase like IL-17 but there aren9t any relation between the disease activity and coronary risk factors such as serum lipids, glucose intolerance and obesity. Since this is a cross sectional study, to determine higher levels of pentraxin in BD patients who also have higher cardiovascular disease incidences, the patients have to be followed in the longer run. To identify these long-term studies to quantified atherosclerosis are required. References Pamuk GE, Pamuk ON, Or€um H, et al. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behcet9s disease? A comparative study. Blood Coagul Fibrinolysis 2010; 21: 113e117. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Behcet9s Syndrome. Semin Arthritis Rheum 2008; 38:1e12. Disclosure of Interest None declared